中华普通外科杂志
中華普通外科雜誌
중화보통외과잡지
CHINESE JOURNAL OF GENERAL SURGERY
2012年
2期
131-133
,共3页
牛坚%赵何伟%郑苏文%严栋梁%张业伟
牛堅%趙何偉%鄭囌文%嚴棟樑%張業偉
우견%조하위%정소문%엄동량%장업위
癌,肝细胞%干细胞%抗原,Thy-1%受体,IGF1型
癌,肝細胞%榦細胞%抗原,Thy-1%受體,IGF1型
암,간세포%간세포%항원,Thy-1%수체,IGF1형
Carcinoma,hepatocellular%Stem cell%Antigen Thy-1%Receptor,IGF type 1
目的 探讨干细胞表面标志物CD90和胰岛素样生长因子1受体(insulin-like growth factor 1 receptor,IGF1 R)在肝癌中的表达情况及其与原发性肝癌的关系.方法 应用免疫组化S-P法检测36例原发性肝癌中CD90、IGF1R的表达,并以20例肝脏血管瘤患者的正常肝组织作对照.随访33例患者,Kaplan-Meier法对患者中位生存期和生存率进行分析.结果 原发性肝癌组织CD90、IGF1R蛋白的阳性表达率分别为63.89％( 23/36)、52.78％( 19/36),显著高于正常肝组织(0/20)、5％ (1/20),二者比较差异有统计学意义(P＜0.05).CD90在UICC临床分期Ⅲ、Ⅳ期中阳性表达率(79.17％)比Ⅰ～Ⅱ期(33.33％)明显增高(P＜0.05),低分化组阳性表达率(76.92％)比高中分化组(56.52％)明显增高(P＜0.05).IGF1R在UICC临床分期Ⅲ、Ⅳ期的患者中阳性表达率(70.83％)比Ⅰ～Ⅱ期(16.67％)明显增高(P＜0.05),低分化组阳性表达率(84.62％)比高分化组(37.38％)明显增高(P＜0.05).CD90阳性表达和IGF1R阳性表达呈显著正相关(P ＜0.05).CD90阳性者术后中位生存期为85 d,而阴性者术后中位生存期为505 d(P ＜0.05),IGF1R阳性者术后中位生存期为100d,而阴性者术后中位生存期为408 d(P ＜0.05). 结论 CD90、IGF1R可能与肝癌的发生发展相关.
目的 探討榦細胞錶麵標誌物CD90和胰島素樣生長因子1受體(insulin-like growth factor 1 receptor,IGF1 R)在肝癌中的錶達情況及其與原髮性肝癌的關繫.方法 應用免疫組化S-P法檢測36例原髮性肝癌中CD90、IGF1R的錶達,併以20例肝髒血管瘤患者的正常肝組織作對照.隨訪33例患者,Kaplan-Meier法對患者中位生存期和生存率進行分析.結果 原髮性肝癌組織CD90、IGF1R蛋白的暘性錶達率分彆為63.89％( 23/36)、52.78％( 19/36),顯著高于正常肝組織(0/20)、5％ (1/20),二者比較差異有統計學意義(P＜0.05).CD90在UICC臨床分期Ⅲ、Ⅳ期中暘性錶達率(79.17％)比Ⅰ～Ⅱ期(33.33％)明顯增高(P＜0.05),低分化組暘性錶達率(76.92％)比高中分化組(56.52％)明顯增高(P＜0.05).IGF1R在UICC臨床分期Ⅲ、Ⅳ期的患者中暘性錶達率(70.83％)比Ⅰ～Ⅱ期(16.67％)明顯增高(P＜0.05),低分化組暘性錶達率(84.62％)比高分化組(37.38％)明顯增高(P＜0.05).CD90暘性錶達和IGF1R暘性錶達呈顯著正相關(P ＜0.05).CD90暘性者術後中位生存期為85 d,而陰性者術後中位生存期為505 d(P ＜0.05),IGF1R暘性者術後中位生存期為100d,而陰性者術後中位生存期為408 d(P ＜0.05). 結論 CD90、IGF1R可能與肝癌的髮生髮展相關.
목적 탐토간세포표면표지물CD90화이도소양생장인자1수체(insulin-like growth factor 1 receptor,IGF1 R)재간암중적표체정황급기여원발성간암적관계.방법 응용면역조화S-P법검측36례원발성간암중CD90、IGF1R적표체,병이20례간장혈관류환자적정상간조직작대조.수방33례환자,Kaplan-Meier법대환자중위생존기화생존솔진행분석.결과 원발성간암조직CD90、IGF1R단백적양성표체솔분별위63.89％( 23/36)、52.78％( 19/36),현저고우정상간조직(0/20)、5％ (1/20),이자비교차이유통계학의의(P＜0.05).CD90재UICC림상분기Ⅲ、Ⅳ기중양성표체솔(79.17％)비Ⅰ～Ⅱ기(33.33％)명현증고(P＜0.05),저분화조양성표체솔(76.92％)비고중분화조(56.52％)명현증고(P＜0.05).IGF1R재UICC림상분기Ⅲ、Ⅳ기적환자중양성표체솔(70.83％)비Ⅰ～Ⅱ기(16.67％)명현증고(P＜0.05),저분화조양성표체솔(84.62％)비고분화조(37.38％)명현증고(P＜0.05).CD90양성표체화IGF1R양성표체정현저정상관(P ＜0.05).CD90양성자술후중위생존기위85 d,이음성자술후중위생존기위505 d(P ＜0.05),IGF1R양성자술후중위생존기위100d,이음성자술후중위생존기위408 d(P ＜0.05). 결론 CD90、IGF1R가능여간암적발생발전상관.
Objective To investigate the expression of CD90,IGF1R in hepatocellular carcinoma.Methods CD90,IGF1R expression were detected by SP immunohistochemical staining in 36 cases of hepatocellular carcinoma,20 cases of normal liver tissue biopsied from patients of chronic cholecystitis undergoing cholecystectomy. Results The positive rate of CD90 (63.89％,23/36),IGF1R (52.78％,19/36) in hepatocellular carcinoma significantly increased (P ＜ 0.05 ); The positive rate of CD90 was higher in UICC Ⅲ - Ⅳ stage group (79.17％ ) than in UICC stage Ⅰ - Ⅱ group (33.33％,P ＜0.05) ;The positive rate of CD90 was higher in low differentiated group (76.92％ ) than in well-differentiated group (56.52％,P ＜0.05).The positive rate of IGF1R was higher in UICC Ⅲ - Ⅳ stage group (70.83％ ) than in UICC stage Ⅰ - Ⅱ group ( 16.67％,P ＜ 0.05 ). The positive rate of IGF1R was higher in low differentiated group (84.62％) than in well-differentiated group (37.38％,P ＜ 0.05 ).The expression of IGF1R was positively correlated with that of CD90 (P ＜ 0.05 ).The median survival of CD90+ patients (85 days) was shorter than CD90- patients ( 505 days ) ( P ＜ 0.05 ).The median survival of IGF1 R + patients (100 days) was shorter than IGF1 R- patients (408 days,P ＜ 0.05). Conclusions CD90 or IGF1R expression correlates positively with the progression of HCC.
